Hepatotoxicity in a 52-week randomized trial of short-term versus long-term treatment with buprenorphine/naloxone in HIV-negative injection opioid users in China and Thailand

Drug and Alcohol Dependence

Volumn 142, Issue , 2014, Pages 139-145

  Lucas, Gregory M ^a   Young, Alicia ^b   Donnell, Deborah ^b   Richardson, Paul ^a   Aramrattana, Apinun ^c   Shao, Yiming ^d   Ruan, Yuhua ^d   Liu, Wei ^e   Fu, Liping ^f   Ma, Jun ^f   Celentano, David D ^g   Metzger, David ^h   Jackson, J Brooks ^a   Burns, David ⁱ  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c Faculty of Medicine Chiang Mai University   (Thailand)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^e Guangxi Centers for Disease Prevention and Control   (China)

^f The Center for Disease Control and Prevention of Xinjiang Uygur Autonomous Region   (China)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Alanine aminotransferase; Buprenorphine naloxone; Hepatitis C virus; Hepatotoxicity; HIV prevention; Injection drug use; Opioid dependence; Safety

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; BUPRENORPHINE PLUS NALOXONE; BUPRENORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHINA; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH STATUS; HEPATITIS B; HEPATITIS C; HUMAN; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SERODIAGNOSIS; SHORT COURSE THERAPY; THAILAND; TREATMENT DURATION; VIRUS HEPATITIS; ADVERSE EFFECTS; BLOOD; DRUG-INDUCED LIVER INJURY; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

ADULT; ALANINE TRANSAMINASE; ANALGESICS, OPIOID; BILIRUBIN; BUPRENORPHINE; CHINA; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; THAILAND; TREATMENT OUTCOME;

EID: 84905565999     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.06.013     Document Type: Article

References (18)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, APA, Washington, DC. fourth ed.
2. Amass L., Kamien J.B., Mikulich S.K. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend. 2001, 61:173-181.
3. Berson A., Fau D., Fornacciari R., Degove-Goddard P., Sutton A., Descatoire V., Haouzi D., Letteron P., Moreau A., Feldmann G., Pessayre D. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J. Hepatol. 2001, 34:261-269.
4. Berson A., Gervais A., Cazals D., Boyer N., Durand F., Bernuau J., Marcellin P., Degott C., Valla D., Pessayre D. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J. Hepatol. 2001, 34:346-350.
5. Bogenschutz M.P., Abbott P.J., Kushner R., Tonigan J.S., Woody G.E. Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults. J. Addict. Med. 2010, 4:211-216.
6. Herve S., Riachi G., Noblet C., Guillement N., Tanasescu S., Goria O., Thuillez C., Tranvouez J.L., Ducrotte P., Lerebours E. Acute hepatitis due to buprenorphine administration. Eur. J. Gastroenterol. Hepatol. 2004, 16:1033-1037.
7. Houdret N., Asnar V., Szostak-Talbodec N., Leteurtre E., Humbert L., Lecomte-Houcke M., Lhermitte M., Paris J.C. Hepatonephritis and massive ingestion of buprenorphine. Acta Clin. Belg. 1999, (Suppl. 1):29-31.
8. Lucas G.M., Beauchamp G., Aramrattana A., Shao Y., Liu W., Fu L., Jackson J.B., Celentano D.D., Richardson P., Metzger D., group f.t.H.s. Short-term safety of buprenorphine/naloxone in HIV-seronegative opioid-dependent Chinese and Thai drug injectors enrolled in HIV Prevention Trials Network 058. Int. J. Drug Policy 2011, 23:162-165.
9. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst. Rev. 2008, CD002207. 10.1002/14651858.CD002207.
10. Mehta S.H., Netski D., Sulkowski M.S., Strathdee S.A., Vlahov D., Thomas D.L. Liver enzyme values in injection drug users with chronic hepatitis C. Digest. Liver Dis. 2005, 37:674-680.
11. Metzger D., Donnell D., Jackson B., Celentano D., Aramrattana A., Shao Y., Rose S., Dye B., Lucas G., Chawarski M., Beauchamp G., Liu T.Y., Burns D., Chen R., Davenny K., Shin K., Liu W., Li Y., Liu S., Hung J.H. One year of counseling supported buprenorphine-naloxone treatment for HIV prevention in opiate dependent injecting drug users showed efficacy in reducing opiate use and injection frequency: HPTN 058 in Thailand and China [Abstract THPE191]. 19th International AIDS Conference 2012.
12. Petry N.M., Bickel W.K., Piasecki D., Marsch L.A., Badger G.J. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am. J. Addict. 2000, 9:265-269.
13. Saxon A.J., Ling W., Hillhouse M., Thomas C., Hasson A., Ang A., Doraimani G., Tasissa G., Lokhnygina Y., Leimberger J., Bruce R.D., McCarthy J., Wiest K., McLaughlin P., Bilangi R., Cohen A., Woody G., Jacobs P. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013, 128:71-76.
14. Schottenfeld R.S., Pakes J., O'Connor P., Chawarski M., Oliveto A., Kosten T.R. Thrice-weekly versus daily buprenorphine maintenance. Biol. Psychiatry 2000, 47:1072-1079.
15. Sullivan L.E., Fiellin D.A. Narrative review: buprenorphine for opioid-dependent patients in office practice. Ann. Intern. Med. 2008, 148:662-670.
16. Substance Abuse and Mental Health Services Administration Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939 2004, Substance Abuse and Mental Health Services Administration, Rockville, MD.
17. Vergara-Rodriguez P., Tozzi M.J., Botsko M., Nandi V., Altice F., Egan J.E., O'Connor P.G., Sullivan L.E., Fiellin D.A., Collaborative B. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J. Acquir. Immune Defic. Syndr. 2011, 56(Suppl. 1):S62-S67.
18. Zuin M., Giorgini A., Selmi C., Battezzati P.M., Cocchi C.A., Crosignani A., Benetti A., Invernizzi P., Podda M. Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. Digest. Liver Dis. 2009, 41:e8-e10.